DIN 02337835 — STALEVO 200 MG; 125 MG; 31.25 MG
STALEVO is a tablet of Carbidopa / Levodopa / Entacapone marketed by SANDOZ CANADA INCORPORATED. The full Carbidopa / Levodopa / Entacapone monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02337835
- Brand name
- STALEVO
- Active ingredient
- Carbidopa / Levodopa / Entacapone
- Strength
- 200 MG; 125 MG; 31.25 MG
- Dosage form
- TABLET
- Route
- ORAL
- Manufacturer
- SANDOZ CANADA INCORPORATED
- Health Canada status
- MARKETED
- Drug class
- Antiparkinsonian agent (dopamine precursor, decarboxylase inhibitor, and COMT inhibitor combination)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Carbidopa / Levodopa / Entacapone products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02337827 | STALEVO | 18.75 MG; 200 MG; 75 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED |
| 02305933 | STALEVO | 200 MG; 50 MG; 12.5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED |
| 02305941 | STALEVO | 25 MG; 100 MG; 200 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED |
| 02305968 | STALEVO | 37.5 MG; 200 MG; 150 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED |